First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Running, not enrolling · Phase 1

Conditions studied: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer

In brief

This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.

Key facts

Study ID

NCT05489237

Run by

IDRX, Inc., a wholly owned subsidiary of GSK, LLC

People needed

276

Starts

2022-08-03

Expected to finish

2027-03-26

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Phase 1
• Male or female participants ≥18 years of age
• Histologically or cytologically confirmed metastatic and/or surgically unresectable GIST
• Documented progression on imatinib (Phase 1)
• Documented pathogenic mutation in KIT OR any PDGFRA mutation other than exon 18 mutations, determined through local testing
• At least one measurable lesion by mRECIST v1.1 for participants with GIST
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Resolution of any toxicities from prior treatment(s) to ≤ Grade 1 by NCI CTCAE v5.0 criteria, or have resolved to baseline, at the time of first dose of study drug.
• Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, or other study procedures and study restrictions.
• Additional for Phase 1b Exploratory Cohorts
• For Cohort 1, progressed on imatinib only (second line therapy) and refused or are ineligible for other standard of care (SOC) therapies.
• For Cohort 2, progressed on both imatinib and sunitinib (third line therapy) or progressed on imatinib, sunitinib, and an additional agent (i.e., regorafenib or ripretinib) (fourth line therapy) or progressed on imatinib, sunitinib, regorafenib, and ripretininb (fifth line or greater therapy)
• For Cohort 3 [US, UK, China, and Japan only], treatment naïve (first line therapy) and refused or are ineligible for other standard of care (SOC) therapies.
• For Cohort 4, met the same criteria as Cohort 2 (third line or greater) and have also had prior treatment with investigational agents NB003 or THE-630 or a line of therapy of bezuclastinib plus sunitinib combination.

You may not qualify if…

• Any prior exposure to the following investigational agents NB003 or THE-630 or bezuclastinib plus sunitinib combination (except for participants treated in Cohort 4 of Phase 1b).
• GIST with no documented mutation in both KIT and PDGFRA genes.
• Primary brain malignancy or known untreated or active central nervous system metastases.
• Has an active uncontrolled infection, including, but not limited to, the requirement for intravenous antibiotics.
• Has significant, uncontrolled, or active cardiovascular disease.

Where it is running

• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — St Louis, Missouri, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Portland, Oregon, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — Leuven, Belgium
• GSK Investigational Site — Beijing, China
• GSK Investigational Site — Guangzhou, China
• GSK Investigational Site — Wuhan, China
• GSK Investigational Site — Bordeaux, France
• GSK Investigational Site — Lyon, France
• GSK Investigational Site — Marseille, France
• GSK Investigational Site — Villejuif, France
• GSK Investigational Site — Berlin, Germany
• GSK Investigational Site — Essen, Germany
• GSK Investigational Site — Milan, Italy
• GSK Investigational Site — Chiba, Japan
• GSK Investigational Site — Kanagawa, Japan
• GSK Investigational Site — Tokyo, Japan
• GSK Investigational Site — Amsterdam, Netherlands
• GSK Investigational Site — Rotterdam, Netherlands
• GSK Investigational Site — Seongnam-si Gyeonggi-do, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.